[HTML][HTML] Clinical implications of co‐occurring prolonged grief disorder in patients with treatment‐resistant major depressive disorder
S Zisook, S Mohamad, G Johnson, I Tal… - World …, 2021 - ncbi.nlm.nih.gov
Prolonged grief disorder (PGD) is now an official diagnosis in both the ICD-11 and the DSM-
5-TR1. It is a distressing and disruptive condition that often occurs concomitantly with …
5-TR1. It is a distressing and disruptive condition that often occurs concomitantly with …
Selective orexin receptor antagonists as novel augmentation treatments for major depressive disorder: evidence for safety and efficacy from a phase 2B study of …
MK Jha - International Journal of Neuropsychopharmacology, 2022 - academic.oup.com
There is a large unmet need for effective treatment of major depressive disorder (MDD), an
often chronic/recurrent disorder that affects 1 in 5 adults during their lifetime in the United …
often chronic/recurrent disorder that affects 1 in 5 adults during their lifetime in the United …
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other" Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial
J Yoon, S Zisook, A Park, GR Johnson… - The Journal of …, 2018 - legacy.psychiatrist.com
Methods: The cost-effectiveness analysis was conducted as part of a randomized clinical
trial, the Veterans Affairs Augmentation and Switching Treatments for Improving Depression …
trial, the Veterans Affairs Augmentation and Switching Treatments for Improving Depression …
Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
PB Hicks, V Sevilimedu, GR Johnson… - Psychiatric …, 2023 - Am Psychiatric Assoc
Background In this secondary analysis of the VA Augmentation and Switching Treatments
for Improving Depression Outcomes (VAST‐D) study we used antidepressant response …
for Improving Depression Outcomes (VAST‐D) study we used antidepressant response …
Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major …
R Jain, F Laliberté, G Germain, M Mahendran… - Journal of Managed …, 2023 - jmcp.org
BACKGROUND: Major depressive disorder (MDD) is a highly prevalent mental health
condition associated with substantial economic burden. Inadequate response to first-line …
condition associated with substantial economic burden. Inadequate response to first-line …
[HTML][HTML] Obesogenic medications and weight gain over 24 weeks in patients with depression: results from the GUIDED study
Weight gain is a common side-effect of medications used to treat major depressive disorder
(MDD). We sought to estimate the frequency of weight gain for obesogenic medications …
(MDD). We sought to estimate the frequency of weight gain for obesogenic medications …
[HTML][HTML] Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major …
About two thirds of the patients with major depressive disorder (MDD) do not sufficiently
respond to monotherapy with antidepressants (ADs) which makes them reliant on further …
respond to monotherapy with antidepressants (ADs) which makes them reliant on further …
Management of treatment-resistant depression in real-world clinical practice settings across Asia
Purpose Consensus is lacking on the management of treatment-resistant depression (TRD),
resulting in significant variations on how TRD patients are being managed in real-world …
resulting in significant variations on how TRD patients are being managed in real-world …
Impact of concurrent posttraumatic stress disorder on outcomes of antipsychotic augmentation for major depressive disorder with a prior failed treatment: VAST-D …
S Mohamed, GR Johnson, V Sevilimedu… - The Journal of clinical …, 2020 - psychiatrist.com
Objective: To determine whether concurrent posttraumatic stress disorder (PTSD) should
affect whether to augment or switch medications when major depressive disorder (MDD) has …
affect whether to augment or switch medications when major depressive disorder (MDD) has …
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
S Zisook, GR Johnson, P Hicks, P Chen… - Depression and …, 2021 - Wiley Online Library
Background This secondary analysis of the VA Augmentation and Switching Treatments for
Depression study compared the continuation phase treatment outcomes of three commonly …
Depression study compared the continuation phase treatment outcomes of three commonly …